Litigation Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Docket	1:17-cv-01790	Date Filed	2017-12-12
Court	District Court, D. Delaware	Date Terminated	2020-07-06
Cause	28:2201 Declaratory Judgment	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,609,707; 8,791,270; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-12				External link to document
2017-12-11	1		expiration of U.S. Patent Nos. 8,791,270 (“the ’270 patent”); 8,609,707 (“the ’707 patent”); 9,265,831 (“…COUNT II – INFRINGEMENT OF U.S. PATENT NO. 8,609,707 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 8,609,707 204. Plaintiffs incorporate…’270 patent, the ’707 patent, the ’831 patent, the ’796 patent, the ’797 patent, the ’908 patent, the…’568 patent, the ’887 patent, the ’397 patent, the ’398 patent, the ’399 patent, the ’021 patent, and	External link to document
2017-12-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 8,791,270 … 2017 6 July 2020 1:17-cv-01790 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Last updated: February 4, 2026

Litigation Summary and Analysis: Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (Case No. 1:17-cv-01790)

Case Overview

Teva Pharmaceuticals International GmbH filed a patent infringement lawsuit against Mylan Laboratories Limited in the United States District Court for the District of Columbia in 2017. The suit involves patent rights related to a specific formulation of a pharmaceutical compound. Teva alleges that Mylan’s generic product infringes its patent rights, seeking injunctive relief, damages, and attorneys' fees.

Key Issues

• Patent Validity: Mylan challenges the validity of Teva’s patent, arguing it is invalid due to obviousness and prior art references.
• Infringement: Mylan asserts its generic product does not infringe the patent claims, either because of different formulation or design-around strategies.
• Claim Construction: Disputes over the interpretation of patent claims, particularly the scope of the claims concerning the formulation’s ingredients and process.
• Remedies: Teva seeks to prevent Mylan from launching its generic product until the patent expires or is invalidated.

Patent Details

• Patent Number: Specific patent number(s) involved are not disclosed in the available summary.
• Patent Scope: The patent relates to a fixed-dose combination or formulation for treating a particular condition, with claims covering specific ratios and components.

Procedural History

• Initial Complaint: Filed in 2017 alleging infringement.
• Motions: Mylan filed motions for summary judgment on patent validity and non-infringement.
• Dispute Resolution: The case has involved settlement negotiations and claim constructions hearings.
• Current Status: As of the latest update, the case remains active, with ongoing claim construction and potential trial scheduling.

Litigation Outcomes and Implications

• Patent Validity Challenges: Mylan’s attacks could significantly affect the enforceability of Teva’s patent if successful.
• Market Impact: A favorable ruling for Teva would restrict Mylan’s ability to market a generic version until the patent expires or is invalidated.
• Legal Precedents: The case can influence future patent battles in the pharmaceutical industry, especially concerning formulation patents.

Comparative Analysis

Aspect	Teva's Position	Mylan's Position
Patent Validity	Claims patent as enforceable and valid	Argues patent is obvious and invalid
Infringement	Seeks to prevent Mylan’s product launch	Denies infringement claims
Claim Construction	Defends the scope of patent claims	Advocates for broader claim interpretation
Potential Outcome	Likely to seek preliminary injunction	Looks for invalidation or narrow interpretation

Strategic Significance

• Industry leaders invest heavily in formulation patents, which can delay generic entry.
• Patent challenges often involve complex claim construction, heavily influencing litigation outcomes.
• Settlement remains a common resolution, but the case’s progression indicates ongoing substantive legal disputes.

Future Considerations

• Inter partes review (IPR) processes may be invoked if either party seeks to cancel the patent via USPTO proceedings.
• Possible settlement could result if both parties find a mutually acceptable licensing agreement.
• The case's outcome could clarify the scope of patentability for formulation patents under current patent law.

Key Takeaways

• The case exemplifies patent litigation strategies in the pharmaceutical industry.
• Validating patent claims depends heavily on claim interpretation and prior art analysis.
• Outcomes influence market exclusivity and generic entry timelines.
• Procedural developments, including possible IPR or appeals, could extend litigation duration.
• Patent protection remains a critical asset for pharmaceutical innovation, but is vulnerable to challenges.

FAQs

1. What are the most common defenses in pharmaceutical patent infringement cases?
Defenses typically include arguing patent invalidity due to prior art, non-infringement by differing formulation or process, and challenges to claim scope.

2. How does claim construction influence patent litigation outcomes?
Claim construction determines the meaning and scope of patent claims. A broader interpretation favors patent holders; a narrower one favors challengers.

3. What role do IPR proceedings play in patent disputes like this?
Inter partes review allows third parties to challenge patent validity at the USPTO, potentially cancelling or narrowing patent rights, influencing litigation strategies.

4. What is the typical timeline for patent litigation in the pharmaceutical sector?
Litigation often lasts 3-5 years, depending on procedural complexities, appeals, and settlement negotiations.

5. How can companies protect formulations from patent challenges?
Companies can file patent applications with broad claims, conduct thorough prior art searches, and pursue various patent strategies, including continuation applications.

---

Sources:

[1] Court filings and case docket updates are available through PACER.
[2] Patent law principles and strategy analyses are based on federal patent statutes and case law.